Asgard Pharmaceuticals Inc. — Canada
Fabless biologics& vaccinemanufacturing
Producing affordable pharmaceuticals through global innovation and Canadian infrastructure.
1914
Connaught Labs founded as a public, not-for-profit vaccine maker
$126M
Federal investment in the Biologics Manufacturing Centre
1
Confirmed partner using that capacity today
Our mission
To produce affordable pharmaceuticals by licensing global innovations and utilizing Canadian biomanufacturing infrastructure.
Affordability
We aim to challenge the dominance of US "Big Pharma" by reducing the burden of high cost vaccines & biologics on the Canadian taxpayer through leveraging domestic manufacturing capabilities.
Our Vision
Become Canada's first agile, cost-efficient bridge for licensing, developing, and commercializing innovative foreign intellectual property in large molecule pharmaceuticals.
History
Canada was once a leader in public vaccine manufacturing
1914
A public leader
Connaught Labs produces antitoxins as a public, not-for-profit institute tied to the University of Toronto.
1990s
Sold off
Privatization and foreign acquisitions (Connaught → Sanofi, Armand Frappier → GSK) dismantle our domestic capacity.
2020
Exposed
COVID-19 reveals that Canada can no longer produce its own vaccines when it matters most.
Today
Underutilized
The federal government invested $126 million in the Biologics Manufacturing Centre, which remains underutilized with only one confirmed partner.
The problem
Canadians pay more, and control less.
$126M
of public manufacturing capacity, with one confirmed partner.
Cost
Even with public and private coverage, patients still pay high out-of-pocket costs, while taxpayers foot inflated bills driven by pharma pricing power.
Fragile health sovereignty
Canada relies on foreign pharma giants, with little control over supply, pricing, or production.
Vulnerable supply chains
Pandemics and geopolitics have exposed our inability to produce critical medicines when it matters most.
Innovation bottleneck
Cutting-edge therapies abroad are delayed or unavailable in Canada due to lack of domestic licensing and trial pathways.
Our model
Fabless, by design.
Like a fabless chipmaker, we don't build factories. We bring proven science to Canada and put existing public infrastructure to work.
License
Late-phase global innovations, licensed for Canadian development and commercialization.
Manufacture
Produced in idle domestic facilities like the Biologics Manufacturing Centre.
Deliver
Affordable, locally made biologics for patients and healthcare systems.
Rebuild domestic biotech
License late-phase global innovations and invest in Canadian-led development and commercialization, building a resilient domestic pipeline.
Deploy idle capacity
Facilities like the Biologics Manufacturing Centre (BMC) represent untapped national capacity.
Slash costs
Avoid traditional R&D overhead and global distribution markups to offer affordable, locally made biologics.
Eliminate price gouging
Minimizing cost allows minimizing excessive markups to patients while still offering high-quality medicines.
What we believe
If drug development is supported by taxpayer dollars, then the public deserves access to its rewards—not just private shareholders.
We believe that public funding should yield public returns.
We believe in a resilient, self-sufficient Canadian pharmaceutical system, free of foreign interference, ready for pandemics and supply chain shocks.
Whether you hold promising IP, operate manufacturing capacity, or share our vision for Canadian health sovereignty, we'd love to hear from you.
Contact Us